Seminars in Colon & Rectal Surgery
Volume 13, Issue 1 , Pages 16-30 , March 2002

Screening for colorectal cancer in the average-risk population

References 

  1. Herrinton LJ, Selby JV, Friedman GD, et al.  Case-control study of digital-rectal screening in relation to mortality from cancer of the distal rectum. Am J Epidemiol. 1995;142:961–964
  2. Hertz REL, Deddish MR, Emerson D. Value of periodic examinations in detecting cancer of the rectum and colon. Postgrad Med. 1960;27:290–294
  3. Winawer SJ, Fletcher RH, Miller L, et al.  Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology. 1997;112:594–642
  4. Shi-Qin Z. Screening and prevention of colorectal cancer in Haining County. Dis Colon Rectum. 1985;28:300–304
  5. Bolt RJ. Sigmoidoscopy in detection and diagnosis in the asymptomatic individual. Cancer. 1971;28:121–122
  6. Selby JV, Friedman GD. Sigmoideoscopy in the periodic health examination of asymptomatic adults. JAMA. 1989;261:595–601
  7. Gilbertsen VA, Nelms JM. The prevention of invasive cancer of the rectum. Cancer. 1978;41:1137–1139
  8. Selby JV, Friedman GD, Quesenberry CP, et al.  A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653–657
  9. Winawer SJ, Miller C, Lightdale CI, et al.  Patient response to sigmoidoscopy: A randomized controlled trial of rigid and flexible sigmoidoscopy. Cancer. 1987;60:1905–1908
  10. Atkin WS, Edwards R, Wardle J, et al.  Randomized trial of ‘once-only’ flexible sigmoidoscopy (FS) screening: Baseline results. Annual Meeting, Brighton, July 10-12, 2000. Colorectal Dis. 2000;2:21; (abstr 73, suppl 1)
  11. Newcomb PA, Norfleet RG, Storer BE, et al.  Screening sigmoideoscopy and colorectal cancer mortality. J Natl Cancer Inst. 1992;84:1572–1575
  12. Shapiro S. Case-control studies of colorectal cancer mortality: Is the case made for screening sigmoidoscopy?. J Natl Cancer Inst. 1992;84:1546–1547
  13. Müller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy. Ann Intern Med. 1995;123:904–910
  14. Müller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. Arch Intern Med. 1995;155:1741–1748
  15. Thiis-Evensen E, Hoff GS, Sauar J, et al.  Population-based surveillance by colonoscopy: Effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol. 1999;34:414–420
  16. Thiis-Evensen E, Wilhelmsen I, Hoff GS, et al.  The psychologic effect of attending a screening program for colorectal polyps. Scand J Gastroenterol. 1999;34:103–109
  17. Atkin WS, Hart A, Edwards R, et al.  Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut. 1998;42:560–565
  18. Atkin WS, Cook CF, Patel R, et al.  Variability in yield of neoplasia in average risk individuals undergoing flexible sigmoidoscopy (FS) screening. Annual Meeting, Brighton, July 10-12, 2000. Colorectal Dis. 2000;2(abstr 11, suppl 1):21
  19. Atkin WS, Cuzick J, Northover JMA, et al.  Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet. 1993;341:736–740
  20. Segnan N, Sciallero S, Bonelli L, et al.  Multicentre randomised controlled trial of ‘once-only’ flexible sigmoidoscopy screening in Italy-score. Endoscopy. 1999;31:E99; (suppl 1)
  21. Gohagan JK, Prorok PC, Kramer BS, et al.  The prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. Cancer. 1995;75:1869–1873
  22. Weissfeld JL, Ling BS, Schoen RE, et al.  Repeat screening flexible sigmoidoscopy in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. 101st Annual Meeting of the American Gastroenterological Association, May 21-24, 2000. Gastroenterology. 2000;118(abstr 2425, suppl 2):A441
  23. Kavanagh AM, Giovannucci EL, Fuchs CS, et al.  Screening endoscopy and risk of colorectal cancer in United States men. Cancer Causes Control. 1998;9:455–462
  24. Vernon SW. Participation in colorectal cancer screening: A review. J Natl Cancer Inst. 1997;89:1406–1422
  25. Cockburn J, Thomas RJS, McLaughlin SJ, et al.  Acceptance of screening for colorectal cancer by flexible sigmoidoscopy. J Med Screening. 1995;2:79–83
  26. Sharma VK, Chockalingham S, Clark V, et al.  Randomized, controlled comparison of two forms of preparation for screening flexible sigmoidoscopy. Am J Gastroenterol. 1997;92:809–811
  27. Atkin WS, Hart A, Edwards R, et al.  Single blind, randomised trial of efficacy and acceptability of oral Picolax versus self administrated phosphate enema in bowel preparation for flexible sigmoidoscopy screening. BMJ. 2000;320:1504–1509
  28. Painter J, Saunders DB, Bell GD, et al.  Depth of insertion at flexible sigmoidoscopy: Implications for colorectal cancer screening and instrument design. Endoscopy. 1999;31:227–231
  29. Rasmussen M, Kronborg O, Fenger C, et al.  Possible advantages and drawbacks of adding flexible sigmoidoscopy to Hemoccult-II in screening for colorectal cancer. Scand J Gastroenterol. 1999;34:73–78
  30. Painter J, Bell GD, Rowland RS, et al.  Colorectal cancer screening: Prospective trial comparing a thinner 100 cm prototype endoscope with a standard 60 cm flexible sigmoidoscope. Gut. 2000;46(suppl II):A79; (abstr T 20
  31. Mensink PBF, Kolkman JJ, van Baarlen J, et al.  Changes in anatomical distribution of colorectal carcinoma over 15 years; clinical considerations. In: March 18-19, 1999;p. 163; Programma voorjaarsvergadering, Nederlandse Vereniging voor gastroenterologie, Veldhoven (abstr)
  32. Obrand DI, Gordon PH. Continued change in the distribution of colorectal carcinoma. Br J Surg. 1998;85:246–248
  33. Collett JA, Platell C, Fletcher DR, et al.  Distal colonic neoplasms predict proximal neoplasia in average-risk, asymptomatic subjects. J Gastroenterol Hepatol. 1999;14:67–71
  34. Levin TR, Palitz A, Grossman S, et al.  Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy. JAMA. 1999;281:1611–1617
  35. Kronborg O. Colon polyps and cancer. Endoscopy. 2000;32:124–130
  36. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med. 1992;326:658–662
  37. Arrigoni A, Pennazio M, Rossini FP. Rectosigmoid polyps as markers of proximal colonic neoplasms: A cost benefit analysis of different diagnostic protocols. Anticancer Res. 1995;15:563–568
  38. Duthie GS, Drew PJ, Hughes MAP, et al.  A UK training programme for nurse practitioner flexible sigmoidoscopy and a prospective evaluation of the practice of the first UK trained nurse flexible sigmoidoscopist. Gut. 1998;43:711–714
  39. Schoenfeld P, Lipscomb S, Crook J, et al.  Accuracy of polyp detection by gastroenterologists and nurse endoscopists during flexible sigmoidoscopy: A randomised trial. Gastroenterology. 1999;117:312–318
  40. Wallace MB, Kemp JA, Meyer F, et al.  Screening for colorectal cancer with flexible sigmoidoscopy by non physician endoscopists. Am J Med. 1999;107:214–218
  41. Sardinha TC, Wexner SD, Gilliland J, et al.  Efficiency and productivity of a sheathed fiberoptic sigmoidoscope compared with a conventional sigmoidoscope. Dis Colon Rectum. 1997;40:1248–1253
  42. Molcahy HE, O'Donoghue DP, Sethi D, et al.  Potential costs and benefits of once-only sigmoidoscopic screening at 60 years in an English population. Disease Week May 1996 and 96th Annual Meeting of the American Gastroenterological Association, San Francisco, California. Gastroenterology. 1996;110(suppl):A563
  43. Marshall JR, Fay D, Lance P. Potential costs of flexible sigmoidoscopy-based colorectal cancer screening. Gastroenterology. 1996;111:1411–1417
  44. Macfarlane B, Leicester R, Romaya C, et al.  Colonoscopy services in the United Kingdom. Endoscopy. 1999;31:409–411
  45. Lieberman DA, Weiss DG, Bond JH, et al.  Veteran Affairs Cooperative Group 380: Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med. 2000;343:162–168
  46. Thiis-Evensen E, Hoff GS, Sauar J, et al.  Flexible sigmoidoscopy or colonoscopy as a screening modality for colorectal adenomas in older age groups? Findings in a cohort of the normal population aged 63-72 years. Gut. 1999;45:834–839
  47. Lemmel GT, Haseman JH, Rex DK, et al.  Neoplasia distal to the splenic flexure in patients with proximal colon cancer. Gastrointest Endosc. 1996;44:109–111
  48. Netzer P, Büttiker U, Pfister M, et al.  Frequency of advanced neoplasia in the proximal colon without an index polyp in the rectosigmoid. Dis Colon Rectum. 1999;42:661–667
  49. Rex DK, Lehman GA, Hawes RH, et al.  Screening colonoscopy in asymptomatic average-risk persons with negative fecal occult blood tests. Gastroenterology. 1991;100:64–67
  50. Johnson DA, Gurney MS, Volpe RJ, et al.  A prospective study of the prevalence of colonic neoplasms in asymptomatic patients with an age-related risk. Am Coll Gastroenterol. 1990;85:969–974
  51. DiSario JA, Foutch PG, Mai HD, et al.  Prevalence and malignant potential of colorectal polyps in asymptomatic, average-risk men. Am J Gastroenterol. 1991;86:941–945
  52. Rasmussen L, Qvist N, Kronborg O. Bowel preparation before colonoscopy. Ugeskr Laeger. 1997;159:933–935
  53. Regev A, Fraser G, Delpre G, et al.  Comparison of two bowel preparations for colonoscopy: Sodium picosulphate with magnesium citrate versus sulphate-free polyethylene glycol lavage solution. Am J Gastroenterol. 1998;93:1478–1482
  54. Van Houten JS, Crane SA, Janardan SK, et al.  A randomized, prospective, double-blind comparison of midazolam (versed) and emulsified diazepam (Dizac) for opioid-based, conscious sedation in endoscopic procedures. Am J Coll Gastroenterol. 1998;93:170–174
  55. Bell GD. Premedication, preparation, and surveillance. Endoscopy. 2000;32:92–100
  56. Brooker JC, Saunders BP, Shah SG, et al.  A new variable stiffness colonoscope makes colonoscopy easier: A randomised controlled trial. Gut. 2000;46:801–805
  57. Froelich F, Gonvers J-J, Vader J-P, et al.  Appropriateness of gastrointestinal endoscopy: Risk of complications. Endoscopy. 1999;31:684–686
  58. Hart R, Classen M. Complications of diagnostic gastrointestinal endoscopy. Endoscopy. 1990;22:229–233
  59. Waye JD, Lewis BS, Yessayan S. Colonoscopy: A prospective report of complications. J Clin Gastroenterol. 1992;15:347–351
  60. Oldenski RJ, Flareau BJ. Colorectal cancer screening. Cancer Epidemiol Prevention Screening. 1992;19:621–635
  61. Winawer SJ, Stewart ET, Zauber AG, et al.  for the National Polyp Study Work Group: A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. N Engl J Med. 2000;342:1766–1772
  62. Rex DK. Barium enema in 1995: Where are we now?. Endoscopy. 1995;27:200–202
  63. Stefánsson T. Diverticulitis of the sigmoid colon. Comprehensive summaries of Uppsala dissertations from the faculty of medicine 501; 1994;
  64. Dodd GD. The role of the barium enema in the detection of colonic neoplasms. Cancer. 1992;70(suppl 5):1272–1275
  65. Jensen J, Kewenter J, Haglind E, et al.  Diagnostic accuracy of double-contrast enema and rectosigmoidoscopy in connection with faecal occult blood testing for the detection of rectosigmoid neoplasms. Br J Surg. 1986;73:961–964
  66. Durdey P, Weston PMT, Williams NS. Colonoscopy or barium enema as initial investigation of colonic disease. Lancet. 1987;2:549–551
  67. Brewster NT, Grieve DC, Saunders JH. Double-contrast barium enema and flexible sigmoidoscopy for routine colonic investigation. Br J Surg. 1994;81:445–447
  68. Fenlon HM, Nunes DP, Schroy PC, et al.  A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps. N Engl J Med. 1999;341:1496–1503
  69. Pescatore P, Glücker T, Delarive J, et al.  Diagnostic accuracy and interobserver agreement of CT colonography (virtual colonoscopy). Gut. 2000;47:126–130
  70. Fletcher JG, Luboldt W. CT colonography and MR colonography: Current status, research directions and comparison. Eur Radiol. 2000;10:786–801
  71. Kay CL, Kulling D, Hawes RH, et al.  Virtual endoscopy—Comparison with colonoscopy in the detection of space-occupying lesions of the colon. Endoscopy. 2000;32:226–232
  72. Rex DK, Vining D, Kopecky KK. An initial experience with screening for colon polyps using spiral CT with and without CT colography (virtual colonoscopy). Gastrointest Endosc. 1999;50:309–313
  73. Mandel JS, Bond JH, Church TR, et al.  Minnesota Colon Cancer Control Study: Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365–1371
  74. Kewenter J, Brevinge H, Engarås B, et al.  Results of screening, rescreening, and follow-up in a prospective randomised study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol. 1994;29:468–473
  75. Hardcastle JD, Chamberlain JD, Robinson MHE, et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477
  76. Kronborg O, Fenger C, Olsen J, et al.  Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471
  77. Selby JV, Friedman GD, Quesenberry CP, et al.  Effect of fecal occult blood testing on mortality from colorectal cancer. Ann Int Med. 1993;118:1–6
  78. Hiwatashi N, Morimoto T, Fukao A, et al.  An evaluation of mass screening using fecal occult blood test for colorectal cancer in Japan: A case-control study. Jpn J Cancer Res. 1993;84:1110–1112
  79. Wahrendorf J, Robra B-P, Wiebelt H, et al.  Zur wirksamkeit des darmkrebs-früherkennungsprogramms. Ergebnisse einer fall-kontroll studie im Saarland. Deutsches Ärzteblatt. 1993;90:2117–2120
  80. Zappa M, Castiglione G, Grazzini G, et al.  Effect of faecal occult blood testing on colorectal mortality: Results of a population-based case-control study in the district of Florence, Italy. Int J Cancer. 1997;73:208–210
  81. Faivre J, Tazi MA, El Mrini T, et al.  Faecal occult blood screening and reduction of colorectal cancer mortality: A case-control study. Br J Cancer. 1999;79:680–683
  82. Mandel JS, Church TR, Ederer F, et al.  Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434–437
  83. Robinson MHE, Hardcastle JD, Moss SM, et al.  The risks of screening: Data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer. Gut. 1999;45:588–592
  84. Mapp TJ, Hardcastle JD, Moss SM, et al.  Survival of patients with colorectal cancer diagnosed in a randomised controlled trial of faecal occult blood screening. Br J Surg. 1999;86:1286–1291
  85. Mandel JS, Church TR, Bond JH, et al.  The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603–1607
  86. Thomas WM, Pye G, Hardcastle JD, et al.  Faecal occult blood screening for colorectal neoplasia: A randomised trial of three days or six days of tests. Br J Surg. 1990;77:277–279
  87. Robinson MH, Thomas WM, Pye G, et al.  Is dietary restriction always necessary in Haemoccult screening for colorectal neoplasia?. Eur J Surg Oncol. 1993;19:539–542
  88. Niv Y. Fecal occult blood test—The importance of proper evaluation. J Clin Gastroenterol. 1990;12:393–395
  89. Kewenter J, Engarås B, Haglind E, et al.  Value of retesting subjects with a positive Hemoccult® in screening for colorectal cancer. Br J Surg. 1990;77:1349–1351
  90. Kewenter J, Björk S, Haglind E, et al.  Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer. 1988;62:645–651
  91. Towler B, Irwig L, Glasziou P, et al.  A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult. BMJ. 1998;317:559–565
  92. Jensen J, Kewenter J, Asztëly M, et al.  Double contrast barium enema and flexible rectosigmoidoscopy: A reliable diagnostic combination for detection of colorectal neoplasm. Br J Surg. 1990;77:270–272
  93. Allison JE:. Review article : Faecal occult blood testing for colorectal cancer. Aliment Pharmacol Ther. 1998;12:1–10
  94. St. John DJB, Young GP, Alexeyeff MA, et al.  Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology. 1993;104:1661–1668
  95. Rozen P, Knaani J, Samuel Z. Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test. Digestive Dis Sci. 1999;44:756–760
  96. Allison JE, Tekawa IS, Ransom LJ, et al.  A comparison of fecal occult-blood tests for colorectal cancer screening. N Engl J Med. 1996;334:155–159
  97. Petty MT, Deacon MC, Alexeyeff MA, et al.  Readability and sensitivity of a new faecal occult blood test in a hospital ward environment. Med J Aust. 1992;156:420–423
  98. Levin B, Hess K, Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997;157:970–976
  99. Young GP. Screening for colorectal cancer: Alternative faecal occult blood tests. Eur J Gastroenterol Hepatol. 1998;10:205–212
  100. Adlercreutz H, Partanen P, Virkola P, et al.  Five guaiac-based tests for occult blood in faeces compared in vitro and in vivo. Scand J Clin Lab Invest. 1984;44:519–528
  101. Barrison IG, Parkins RA. The clinical value of Haemoccult and Fecatwin in the detection of colorectal neoplasia in hospital and general practice patients. Postgrad Med J. 1985;61:701–704
  102. Pye G, Jackson J, Thomas WM, et al.  Comparison of Coloscreen Self-test® and Haemoccult® faecal occult blood tests in the detection of colorectal cancer in symptomatic patients. Br J Surg. 1990;77:630–631
  103. Hunter W, Farmer A, Mant D, et al.  The effect of self-administered faecal occult blood tests on compliance with screening for colorectal cancer: Results of a survey of those invited. Fam Pract. 1991;8:367–372
  104. Verne J, Kettner J, Mant D, et al.  Self-administered faecal occult blood tests do not increase compliance with screening for colorectal cancer: Results of a randomised controlled trial. Eur J Cancer Prev. 1993;2:301–305
  105. Uhlig K, Lampe J, Jacobasch K-H. Früerkennung kolorektaler Karzinoma durch den Nachweis von okkultem Blut im Stuhl mit Krypto-Haem SSW. Z gesamte Inn Med. 1986;41:660–663
  106. Robinson MHE, Marks CG, Farrands PA, et al.  Population screening for colorectal cancer: Comparison between guaiac and immunological faecal occult blood tests. Br J Surg. 1994;81:448–451
  107. Saito H, Soma Y, Koeda J, et al.  Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer. 1995;61:465–469
  108. Saito H, Soma Y, Nakajima M, et al.  A case-control study evaluating occult blood screening for colorectal cancer with Hemoccult test and an immunochemical hemagglutination test. Oncol Rep. 2000;7:815–819
  109. St. John DJB, Sinatra MA, Young GP, et al.  A further evaluation of the new immunochemical fecal occult blood test Flexure® obt. American Gastroenterological Association Annual Meeting during Digestive Disease Week, New Orleans; May 1998; (abstr 2457)
  110. Castiglione G, Sala P, Ciatto S, et al.  Comparative analysis of results of guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening in two oncological institutions. Eur J Cancer Prev. 1994;3:399–405
  111. Robinson MHE, Marks CG, Farrands PA, et al.  Screening for colorectal cancer with an immunological faecal occult blood test: 2 year follow-up. Br J Surg. 1996;83:500–501
  112. Yamamoto M, Nakama H. Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods. Hepatogastroenterology. 2000;47:396–399
  113. Weller D, Thomas D, Hiller J, et al.  Screening for colorectal cancer using an immunochemical test for faecal occult blood: Results of the first 2 years of a South Australian programme. Aust NZ J Surg. 1994;64:464–469
  114. Jeanson A, Jamart J, Maisin JM, et al.  Assessment of the new immunological test Hemoblot for detecting occult blood in faeces. Eur J Cancer Prev. 1994;3:407–412
  115. Nakama H, Fattah A, Zhang B, et al.  A comparative study of immunochemical fecal tests for detection of colorectal adenomatous polyps. Hepatogastroenterology. 2000;47:386–389
  116. Greenberg PD, Bertario L, Gnauck R, et al.  A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol. 2000;95:1331–1338
  117. Turunen MJ, Liewendahl K, Partanen P, et al.  Immunological detection of fecal occult blood in colorectal cancer. Br J Cancer. 1984;49:141–148
  118. Häkkinen I, Paasivuo R, Partanen P. Screening of colorectal tumours using an improved faecal occult blood test. Quantitative aspects. Gut. 1988;29:1194–1197
  119. Ahlquist DA, McGill DB, Schwartz S, et al.  Fecal blood levels in health and disease. A study using HemoQuant. N Engl J Med. 1985;312:1422–1428
  120. St. John DJB, Young GP, McHutchinson JG, et al.  Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia. Ann Int Med. 1992;117:376–382
  121. Rozen P, Knaani J, Papo N. Evaluation and comparison of an immunochemical and a guaiac faecal occult blood screening test for colorectal neoplasia. Eur J Cancer Prev. 1995;4:475–481
  122. Sieg A, Hertel A, John MR, et al.  Screening for colorectal neoplasms with a new immunological human faecal haemoglobin and albumin test. Eur J Cancer Prev. 1998;7:279–285
  123. Lüthgens K, Maier A, Kampert I, et al.  Hemoglobin-haptoglobin-complex: A highly sensitive assay for the detection of fecal occult blood. Clin Lab. 1998;44:543–551
  124. Sieg A, Thoms C, Lüthgens K, et al.  Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces. Int J Colorectal Dis. 1999;14:267–271
  125. Miyoshi H, Ohshiba S, Asada S, et al.  Immunological determination of fecal hemoglobin and transferrin levels: A comparison with other fecal occult blood tests. Am J Gastroenterol. 1992;87:67–73
  126. Winawer SJ, Flehinger BJ, Schottenfield D, et al.  Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst. 1993;85:1311–1318
  127. Smart CR. Critique of the early cancer detection guidelines of the US Preventive Services Task Force and of the National Cancer Institute. Mayo Clin Proc. 1990;65:892–898 (editorial)
  128. Byers T, Levin B, Rothenberger D, et al.  American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer: American Cancer Society Guidelines for screening and surveillance for early detection of colorectal polyps and cancer: Update 1997. CA Cancer J Clin. 1997;47:154–160
  129. Ransohoff DF, Lang CA. A model to assess neoplasm detection in colon cancer screening. American Gastroenterological Association Annual Meeting during Digestive Disease Week, New Orleans. Gastroenterology. 1988;94:A367; (abstr)
  130. Macrae F. Epidemiology and early detection of colorectal cancer. Curr Opin Oncol. 1991;3:711–718
  131. Verne JECW, Aubrey R, Love SB, et al.  Population based randomised study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing. BMJ. 1998;317:182–185
  132. Brevinge H, Lindholm E, Buntzen S, et al.  Screening for colorectal neoplasia with faecal occult blood testing compared with flexible sigmoidoscopy directly in a 55-56 year old population. Int J Colorectal Dis. 1997;12:291–295
  133. Berry DP, Clarke P, Hardcastle JD, et al.  Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg. 1997;84:1274–1276
  134. Rasmussen M, Kronborg O. Diagnostic yield of CRC in screening with once flexible sigmoidoscopy (FS) + Hemoccult-II (H-II) compared to biennial H-II alone. 7th UEGW oral presentations. Gut. 1999;45:A18; (abstr 19.02)
  135. Launoy G, Smith TC, Duffy SW, et al.  Colorectal cancer mass-screening: Estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. Int J Cancer. 1997;73:220–224
  136. Tazi MA, Faivre J, Lejeune C, et al.  Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test. Eur J Cancer Prev. 1999;8:131–135
  137. Moss SM, Hardcastle JD, Coleman DA, et al.  Interval cancers in a randomised controlled trial of screening for colorectal cancer using a faecal occult blood test. Int J Epidemiol. 1999;28:386–390
  138. Kronborg O. Screening for colorectal neoplasia. Ital J Gastroenterol Hepatol. 1999;31:27–129
  139. Church TR, Ederer F, Mandel JS. Fecal occult blood screening in the Minnesota Study: Sensitivity of the screening test. J Natl Cancer Inst. 1997;89:1440–1448
  140. Yokoyama S, Shatney CH, Mochizuki H, et al.  The potential role of fecal carbonic anhydrase II in screening for colorectal cancer. Am Surg. 1997;63:243–347
  141. Røseth AG, Kristinsson J, Fagerhol MK, et al.  Faecal calprotectin: A novel test for the diagnosis of colorectal cancer?. Scand J Gastroenterol. 1993;28:1073–1076
  142. Kronborg O, Ugstad M, Fuglerud P, et al.  Faecal calprotectin levels in a high-risk population for colorectal neoplasia. Gut. 2000;46:795–800
  143. Ahlquist DA. Molecular stool screening for colorectal cancer. BMJ. 2000;321:254–255 (editorial)
  144. Kronborg O. Screening for colorectal cancer. A short review. In:  Jakobsen A editors. Colorectal Cancer. Current Status and Future Perspectives. First Nordic Symposium on Colorectal Cancer. Bøhm Offset: Denmark; 1999;p. 21–47
  145. Dutta SK, Padmanabhan PN. Noninvasive detection of colorectal cancer by molecular tools: Coming of age. Gastroenterology. 1998;114:1333–1334 (editorial)
  146. Gnauck R. Screening for colon cancer in Germany. Tumori. 1995;81(suppl):30–37
  147. Advisory Committee on Cancer Prevention: Recommendations on cancer screening in the European Union. Eur J Cancer. 2000;36:1473–1478
  148. Simon JB. Should all people over the age of 50 have regular fecal occult-blood tests? Clinical debate. N Engl J Med. 1998;338:1151–1152
  149. Hardcastle JD, Farrands PA, Balfour TW, et al.  Controlled trial of faecal occult blood testing in the detection of colorectal cancer. Lancet. 1983;2:1–4
  150. Kronborg O, Fenger C, Søndergaard O, et al.  Initial mass screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen in Denmark. Scand J Gastroenterol. 1987;22:677–686
  151. Tazi MA, Faivre J, Dassonville F, et al.  Participation in faecal occult blood screening for colorectal cancer in a well defined French population: Results of five screening rounds from 1988 to 1996. J Med Screen. 1997;4:147–151
  152. Mant D, Fitzpatrick R, Hogg A, et al.  Experiences of patients with false positive results from colorectal cancer screening. Br J Gen Pract. 1990;40:423–425
  153. Lindholm E, Berglund B, Kewenter J, et al.  Worry associated with screening for colorectal carcinomas. Scand J Gastroenterol. 1997;32:238–245
  154. Wagner JL, Tunis S, Brown M, et al.  Cost-effectiveness of colorectal cancer screening in average-risk adults. In:  Young GP,  Rozen P,  Levin B editor. Prevention and Early Detection of Colorectal Cancer. London: Saunders; 1996;p. 321–341
  155. Kronborg O. Screening for early colorectal cancer. World J Surg. 2000;24:1069–1074
  156. Gyrd-Hansen D, Søgaard J, Kronborg O. Colorectal cancer screening: Efficiency and effectiveness. Health Econ. 1998;7:9–20
  157. Gyrd-Hansen D. The relative economics of screening for colorectal cancer, breast cancer and cervical cancer. Oncol Hematol. 1999;32:133–144
  158. Anwar S, Hall C, Elder JB. Screening for colorectal cancer: Present, past and future. Eur J Surg Oncol. 1998;24:477–486
  159. Gyrd-Hansen D, Søgaard J, Kronborg O. Analysis of screening data: Colorectal cancer. Int J Epidemiol. 1997;26:1172–1181
  160. Robinson MHE, Marks CG, Farrands PA, et al.  Is an immunological faecal occult blood test better than Hemoccult? A cost-benefit study. Eur J Surg Oncol. 1995;21:261–264
  161. Gyrd-Hansen D. Fecal occult blood tests. A cost-effectiveness analysis. Int J Technol Assess Health Care. 1998;14:290–301
  162. Fric P, Zavoral M, Dvorakova H, et al.  An adapted program of colorectal cancer screening—7 years experience and cost-benefit analysis. Hepatogastroenterology. 1994;41:413–416
  163. Bech K, Kronborg O. The bed-day requirement in connection with screening for colorectal cancer. Report from the first five years of a randomized population investigation. Ugeskr Laeger. 1992;154:696–699
  164. Whynes DK, Walker AR, Chamberlain JO, et al.  Screening and the costs of treating colorectal cancer. Br J Cancer. 1993;68:965–968
  165. Bolin TD. Cost benefit of early diagnosis of colorectal cancer. Scand J Gastroenterol. 1996;31(suppl 220):142–146

☆ Address reprint requests to Ole Kronborg, Professor, Surgical Department A, Odense University Hospital, DK-5000 Odense C, Denmark; e-mail: Ole.Kronborg@DADLNET.DK.

PII: S1043-1489(02)70003-1

Seminars in Colon & Rectal Surgery
Volume 13, Issue 1 , Pages 16-30 , March 2002

Article Tools